The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that therapeutic responses may be improved via its modulation (13, 14)”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [14]
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [19]
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [26]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes Th17 cell differentiation in the LP (1, 13, 14) also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig.”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“S6A) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19).”
BackgroundSelf-citationInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citation
Research works printed but not linked: 1
- 10.1073/pnas.1113744109 · DOI · Paper page
Cited by
Items 601–700 of 1,012
Tian, T., Zhao, Y., Yang, Y., Wang, T., Jin, S., Guo, J., & Liu, Z. (2020) · PubMed Central · Cited by 67
Rutkowski, M. R., Svoronos, N., Perales‐Puchalt, A., & Conejo-Garcia, J. R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.011 · Cited by 64
The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop?
Ser, H., Letchumanan, V., Goh, B. H., Wong, S. H., & Lee, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.519836 · Cited by 63
Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context
Liu, Y., Niu, L., Li, N., Wang, Y., Liu, M., Su, X., Bao, X., Yin, B., & Shen, S. (2023) · Advanced Science · doi:10.1002/advs.202205641 · Cited by 60
Biofilm and Cancer: Interactions and Future Directions for Cancer Therapy
Choi, E., Murray, B., & Choi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612836 · Cited by 62
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
Bordon, Y. (2013) · Nature reviews. Immunology · doi:10.1038/nri3591 · Cited by 58
The Microbiota, Chemical Symbiosis, and Human Disease
Redinbo, M. R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.011 · Cited by 59
The Human Microbiota and Prostate Cancer: Friend or Foe?
Massari, F., Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., López-Beltrán, A., Cheng, L., Battelli, N., et al. (2019) · Cancers · doi:10.3390/cancers11040459 · Cited by 62
Gut microbiome and CAR-T therapy
Abid, M. B., Shah, N. N., Maatman, T. C., & Hari, P. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0155-8 · Cited by 59
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Swan, D., Gurney, M. E., Krawczyk, J., Ryan, A. E., & O'Dwyer, M. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000350 · Cited by 64
The relationship between gastrointestinal cancers and the microbiota
LaCourse, K. D., Johnston, C. D., & Bullman, S. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30362-9 · Cited by 56
Chemotherapy, immunity and microbiota—a new triumvirate?
Karin, M., Jobin, C., & Balkwill, F. R. (2014) · Nature Medicine · doi:10.1038/nm.3473 · Cited by 64
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 60
The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice
Asseri, A. H., Bakhsh, T., Abuzahrah, S. S., Ali, S., & Rather, I. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1208044 · Cited by 60
Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity
Cario, E. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000202 · Cited by 59
Botticelli, A., Zizzari, I., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2017) · Oncotarget · doi:10.18632/oncotarget.12985 · Cited by 56
Tuning cancer fate: the unremitting role of host immunity
Calì, B., Molon, B., & Viola, A. (2017) · Open Biology · doi:10.1098/rsob.170006 · Cited by 61
Food, microbiome and colorectal cancer
Niederreiter, L., Adolph, T. E., & Tilg, H. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.03.030 · Cited by 59
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 58
The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities
Chambers, L., Bussies, P. L., Vargas, R., Esakov, E. L., Tewari, S., Reizes, O., & Michener, C. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01079-x · Cited by 62
The role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 62
Liu, T., Wu, Y., Wang, L., Pang, X., Zhao, L., Yuan, H., & Zhang, C. (2019) · mBio · doi:10.1128/mbio.02903-18 · Cited by 56
Čierniková, S., Mego, M., & Chovanec, M. (2021) · Cancers · doi:10.3390/cancers13040782 · Cited by 60
Mitochondria and Antibiotics: For Good or for Evil?
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Talaverón-Rey, M., Suárez-Carrillo, A., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2021) · Biomolecules · doi:10.3390/biom11071050 · Cited by 61
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Self-citationGut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Sansone, C., Bruno, A., Piscitelli, C., Baci, D., Fontana, A., Brunet, C., Noonan, D. M., & Albini, A. (2021) · Cells · doi:10.3390/cells10020231 · Cited by 58
A systematic review of microbial markers for risk prediction of colorectal neoplasia
Yu, L., Zhao, G., Wang, L., Zhou, X., Sun, J., Li, X., Zhu, Y., He, Y., Kofonikolas, K., Bogaert, D., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01740-7 · Cited by 54
Potential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 55
Liao, Q., Zhou, X., Wu, L., Yang, Y., Zhu, X., Liao, H., Zhang, Y., Lian, W., Zhang, F., Wang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181243 · Cited by 59
Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies
Leal‐Lopes, C., Velloso, F. J., Campopiano, J. C., Sogayar, M. C., & Correa, R. G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/284680 · Cited by 57
Immunotherapy Not Working? Check Your Microbiota
West, N. R., & Powrie, F. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.010 · Cited by 55
Erdman, S. E., & Poutahidis, T. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.05.007 · Cited by 58
Microbiota and chronic inflammatory arthritis: an interwoven link
Diamanti, A. P., Rosado, M. M., Laganà, B., & D’Amelio, R. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0989-3 · Cited by 58
Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy
Li, W., Deng, X., & Chen, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644454 · Cited by 57
Metabolic regulation on the immune environment of glioma through gut microbiota
Lyu, Y., Yang, H., & Liang, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.005 · Cited by 58
Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54
“By altering the integrity of the intestinal barrier, hence promoting the translocation of distinct Gram bacteria, CTX contributed to mount effector pathogenic CXCR3+CCR6+ (IL17IFNγ) Th17 and a cytotoxic CD8 T cell (CTL) response associated with tumor control [11, 13].”
BackgroundSelf-citationPeric, Z., Botti, S., Stringer, J., Krawczyk, J., van der Werf, S., van Biezen, A., Aljurf, M., Murray, J., Liptrott, S., Greenfield, D. M., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0137-1 · Cited by 54
Kabwe, M., Dashper, S. G., Bachrach, G., & Tucci, J. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab017 · Cited by 55
The Opposing Forces of the Intestinal Microbiome and the Emerging Pathobiome
Defazio, J., Fleming, I. D., Shakhsheer, B., Zaborina, O., & Alverdy, J. C. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.08.002 · Cited by 54
The Microbiome, Systemic Immune Function, and Allotransplantation
Nellore, A., & Fishman, J. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00063-15 · Cited by 57
Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R., & ElRakaiby, M. T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530216 · Cited by 56
The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar, Y., Saadat, Y. R., Khatibi, S. M. H., Özkan, T., Vahed, F. Z., Nariman‐Saleh‐Fam, Z., Gargari, B. P., Sunguroğlu, A., & Vahed, S. Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116680 · Cited by 56
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Carbone, C., Piro, G., Noia, V. D., D’Argento, E., Vita, E., Ferrara, M. G., Pilotto, S., Milella, M., Cammarota, G., Gasbarrini, A., et al. (2019) · Mediators of Inflammation · doi:10.1155/2019/7652014 · Cited by 56
Xie, Z., Bai, Y., Chen, G., Rui, Y., Chen, D., Sun, Y., Zeng, X., & Liu, Z. (2020) · Food & Function · doi:10.1039/d0fo02272a · Cited by 54
Shouval, R., Waters, N. R., Gomes, A. L. C., Brambilla, C. Z., Fei, T., Devlin, S. M., Nguyen, C. L., Markey, K. A., Dai, A., Slingerland, J. B., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1254 · Cited by 56
Intestinal inflammation induced by oral bacteria
Cao, X. (2017) · Science · doi:10.1126/science.aap9298 · Cited by 55
Kovàcs, T., Mikó, E., Ujlaki, G., Yousef, H., Csontos, V., Uray, K., & Bai, P. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10013-3 · Cited by 56
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 57
Obesity and the gut microbiome: pathophysiological aspects
Bradlow, H. L. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0063 · Cited by 52
Human diseases, immunity and the oral microbiota—Insights gained from metagenomic studies
Idris, A., Hasnain, S. Z., Huat, L. Z., & Koh, D. S. Q. (2016) · Oral Science International · doi:10.1016/s1348-8643(16)30024-6 · Cited by 57
Disruptive physiology: olfaction and the microbiome–gut–brain axis
Bienenstock, J., Kunze, W., & Forsythe, P. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12348 · Cited by 58
Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer
Netea, M. G., Joosten, L. A. B., & van der Meer, J. W. M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0217-064rr · Cited by 60
Kareva, I. (2019) · Stem Cells · doi:10.1002/stem.3051 · Cited by 48
Targeting tumor-resident mast cells for effective anti-melanoma immune responses
Kaesler, S., Wölbing, F., Kempf, W. E., Skabytska, Y., Köberle, M., Volz, T., Sinnberg, T. W., Amaral, T. M. S., Möckel, S. M. C., Yazdi, A. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125057 · Cited by 55
Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury
Mosedale, M., & Watkins, P. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01297 · Cited by 53
Immune reconstitution after T-cell replete HLA-haploidentical transplantation
McCurdy, S. R., & Luznik, L. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.03.005 · Cited by 52
Oroian, B. A., Ciobica, A. S., Timofte, D. V., Ștefănescu, C., & Șerban, I. L. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5599265 · Cited by 57
Tumor microbiome diversity influences papillary thyroid cancer invasion
Yuan, L., Yang, P., Wei, G., Hu, X., Chen, S., Lu, J., Yang, L. J., He, X., & Bao, G. (2022) · Communications Biology · doi:10.1038/s42003-022-03814-x · Cited by 52
Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation
Boucher, E., Plazy, C., Richard, M. L., Suau, A., Mangin, I., Cornet, M., Aldebert, D., Toussaint, B., & Hannani, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104224 · Cited by 53
Self-citationWadan, A.-H. S., El‐Aziz, M. K. A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04155-2 · Cited by 60
The Challenge and Potential of Metagenomics in the Clinic
Mulcahy, H., & Workentine, M. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00029 · Cited by 57
Heterogeneity of colon cancer: from bench to bedside
Merlano, M. C., Granetto, C., Fea, E., Ricci, V., & Garrone, O. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000218 · Cited by 56
Sadowska‐Klasa, A., Piekarska, A., Prejzner, W., Bieniaszewska, M., & Hellmann, A. R. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3205-5 · Cited by 54
Impact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Pezo, R. C., Wong, M., & Martin, A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819870911 · Cited by 55
Guan, X., Ma, F., Sun, X., Li, C., Li, L., Liang, F., Li, S., Yi, Z., Liu, B., & Xu, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00902 · Cited by 57
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
Kim, J., Chae, C.-S., Kim, G.-C., Hwang, W., Hwang, J., Hwang, S., Kim, Y., Ahn, Y., Park, S., Jun, C., et al. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.01.002 · Cited by 54
The Future of Microbiome‐Based Therapeutics in Clinical Applications
Sharma, A., Das, P., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1677 · Cited by 53
Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A review
Nagasaka, M., Sexton, R. E., Alhasan, R., Rahman, S. B., Azmi, A. S., & Sukari, A. W. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102841 · Cited by 54
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 53
Systemic Immunoregulatory Consequences of Gut Commensal Translocation
McPherson, A. C., Pandey, S. P., Bender, M. J., & Meisel, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.12.005 · Cited by 49
Qu, J., Sun, Z., Chen, P., Li, D., Yan, W., Xu, Z., Hou, Y., Shen, S., Chen, P., & Wang, T. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59262 · Cited by 51
Li, M., Wang, X., Wang, Y., Bao, S., Chang, Q., Liu, L., Zhang, S., & Sun, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797634 · Cited by 52
Gut microbiota in systemic lupus erythematosus: A fuse and a solution
Chen, Y., Lin, J., Xiao, L., Zhang, X., Zhao, L., Wang, M., & Li, L. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102867 · Cited by 56
De-coding the complex role of microbial metabolites in cancer
Escriva, P. P., Bernardino, C. C. T., & Letellier, E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115358 · Cited by 54
Biomarkers and Immunotherapeutic Targets in Glioblastoma
Hung, A. L., Garzón-Muvdi, T., & Lim, M. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.011 · Cited by 53
Dubin, K. A., Mathur, D., McKenney, P. T., Taylor, B. P., Littmann, E. R., Peled, J. U., van den Brink, M. R. M., Taur, Y., Pamer, E. G., & Xavier, J. B. (2019) · Infection and Immunity · doi:10.1128/iai.00102-19 · Cited by 52
Gut microbiome and cancer immunotherapy
Sun, J., Yin, T., Zhou, J., Jiang, X., & Lu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29359 · Cited by 52
Uchiyama, A. A. T., Silva, P. A. I. A., Lopes, M. S. M., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimenta, J. R., Machado, L. M., Shimba, D. S., & Peixoto, R. D. (2021) · Current Oncology · doi:10.3390/curroncol28010076 · Cited by 56
The Role of Respiratory Microbiota in Lung Cancer
Wang, D., Cheng, J., Zhang, J., Zhou, F., He, X., Shi, Y., & Tao, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.51376 · Cited by 52
Interplay between viruses and bacterial microbiota in cancer development
Vyshenska, D., Lam, K. C., Shulzhenko, N., & Morgun, A. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.05.003 · Cited by 52
Zidi, O., Souai, N., Raies, H., Ayed, F. B., Mézlini, A., Mezrioui, S., Tranchida, F., Sabatier, J., Mosbah, A., Cherif, A., et al. (2021) · Molecules · doi:10.3390/molecules26082266 · Cited by 52
Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?
Zha, C., Peng, Z., Huang, K., Tang, K., Wang, Q., Zhu, L. J., Che, B., Li, W., Xu, S., Huang, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196217 · Cited by 51
Then, C. K., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S. M., Bremner, D. M., Roberts, K. S., Smith, E. E., Heidari, Z., et al. (2024) · Microbiome · doi:10.1186/s40168-024-01804-1 · Cited by 52
Ma, C., Zhang, Q., & Greten, T. F. (2017) · FEBS Journal · doi:10.1111/febs.14209 · Cited by 54
The Role of the Gut Microbiome in Colorectal Cancer
Chen, G. (2018) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0037-1602239 · Cited by 55
Combination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 54
Microbiome in cancer progression and therapy
Andreeva, N., Gabbasova, R. R., & Grivennikov, S. I. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.001 · Cited by 49
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 49
Harnessing the Intestinal Microbiome for Optimal Therapeutic Immunomodulation
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., & Zitvogel, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0987 · Cited by 47
Self-citationExploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
Majchrzak, K., Nelson, M. H., Bailey, S. R., Bowers, J. S., Yu, X.-Z., Rubinstein, M. P., Himes, R. A., & Paulos, C. M. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1797-6 · Cited by 47
Considerations for successful cancer immunotherapy in aged hosts
Hurez, V., Padrón, Á., Svatek, R. S., & Curiel, T. J. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.10.002 · Cited by 46
Role of Microbiome in Carcinogenesis Process and Epigenetic Regulation of Colorectal Cancer
Farhana, L., Banerjee, H. N., Verma, M., & Majumdar, A. P. N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8751-1_3 · Cited by 54
The Role of the Human Microbiome in Chemical Toxicity
Koontz, J. M., Dancy, B. C. R., Horton, C. L., Stallings, J. D., DiVito, V. T., & Lewis, J. A. (2019) · International Journal of Toxicology · doi:10.1177/1091581819849833 · Cited by 51
Liu, Y., & Lou, X. (2020) · Clinics · doi:10.6061/clinics/2020/e1277 · Cited by 51
Metadata
- Authors
- Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Doré, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Agency for Science, Technology and Research (SG)
- Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France.
- Service de Microbiologie, Institut Gustave Roussy, Villejuif, France.
- Institut Gustave Roussy (FR)
- Institut Pasteur (FR)
- Nimalerie Centrale, Institut Pasteur, Paris, France.
- Institut National de la Recherche Agronomique, Micalis–UMR1319, 78350 Jouy-en-Josas, France.
- Centre National de la Recherche Scientifique (FR)
- Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, Marseille, France.
- Université d'Orléans (FR)
- University of Alabama at Birmingham (US)
- AgroParisTech (FR)
- Corresponding author
- Ghiringhelli, François
- Zitvogel, Laurence
- ORCID
- Mignot, Grégoire
- Yamazaki, Takahiro
- Daillère, Romain
- Hannani, Dalil
- Pfirschke, Christina
- Engblom, Camilla
- Schlitzer, Andreas
- Ginhoux, Florent
- Woerther, Paul-Louis
- Eberl, Gérard
- Clermont, Dominique
- Opolon, Paule
- Ryffel, Bernhard
- Elson, Charles O.
- Kroemer, Guido
- Lepage, Patricia
- Boneca, Ivo Gomperts
- Ghiringhelli, François
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 971-976
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4048947
- OpenAlex
- W2059128083
- Cited by
- 2,050
- References
- 43
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 176 · 2023: 216 · 2022: 234 · 2021: 217 · 2020: 220 · 2019: 183 · 2018: 137 · 2017: 116 · 2016: 98 · 2015: 101 · 2014: 69 · 2013: 6
- FWCI
- 40.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- HAL AMU (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-11-PHUC-0002)
- National Cancer Institute (P50CA086355)
- National Institute of Allergy and Infectious Diseases (R01AI084880)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK071176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cyclophosphamide, gut microbiota, antitumor immunity, Gram-positive bacteria, Th17 cells, memory T cells, secondary lymphoid organs, bacterial translocation, germ-free mice, antibiotic therapy, adoptive transfer, small intestine
- MeSH terms
- Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cyclophosphamide, Germ-Free Life, Gram-Positive Bacteria, Immunologic Memory, Immunosuppressive Agents, Intestine, Small, Lymphoid Tissue, Neoplasms, Bacterial Translocation, Adoptive Transfer, Mice, Th17 Cells, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.